Harvard Bioscience, Inc. (FRA:HBI0)

Germany flag Germany · Delayed Price · Currency is EUR
4.080
-0.160 (-3.77%)
At close: Mar 13, 2026
Market Cap18.68M -27.3%
Revenue (ttm)73.71M -8.1%
Net Income-48.29M
EPS-10.90
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volumen/a
Open4.080
Previous Close4.240
Day's Range4.080 - 4.080
52-Week Range2.140 - 8.400
Betan/a
RSI38.58
Earnings DateMay 4, 2026

About Harvard Bioscience

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including d... [Read more]

Industry Laboratory Analytical Instruments
Founded 1901
Employees 339
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol HBI0

Financial Performance

In 2025, Harvard Bioscience's revenue was $86.55 million, a decrease of -8.06% compared to the previous year's $94.14 million. Losses were -$56.70 million, 357.1% more than in 2024.

Financial numbers in USD Financial Statements

News

Harvard Bioscience Announces Fourth Quarter and Full-Year 2025 Financial Results

Fourth Quarter 2025 Revenues of $23.7M and Gross Margin of 59.7% Full Year 2025 Revenues of $86.6M and Gross Margin of 57.7% Interim CFO Mark Frost Appointed CFO on Permanent Basis Introduces Full Yea...

17 days ago - GlobeNewsWire

Harvard Bioscience Announces Reverse Stock Split

Harvard Bioscience's common stock is expected to begin trading on a post-split adjusted basis on March 16, 2026 HOLLISTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: H...

22 days ago - GlobeNewsWire

Harvard Bioscience to Participate in KeyBanc's Virtual Healthcare Forum

HOLLISTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that John Duke, President and Chief Executive Officer, and Mark Frost, Interim Chief Financ...

26 days ago - GlobeNewsWire

Harvard Bioscience Schedules Fourth Quarter 2025 Earnings Conference Call for March 12, 2026 at 8:00 AM ET

HOLLISTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2025, before the market opens on Marc...

4 weeks ago - GlobeNewsWire

Harvard Bioscience Announces Preliminary Fourth Quarter Financial Results, Positive Outlook for 2026 & Outlines Long-Term Strategic Focus Areas

Reports preliminary fourth quarter revenue in line with guidance, gross margin at high end of guidance, and strong year over year adjusted EBITDA performance Expects year over year revenue growth and ...

6 weeks ago - GlobeNewsWire

Harvard Bioscience Announces Strategic Consolidation of Manufacturing Operations to Improve Efficiency and Support Long-Term Growth

Streamlining production footprint and improving manufacturing efficiency through phased closure of Holliston, MA plant  Initiative expected to deliver approximately $3 million in cost savings in 2027 ...

2 months ago - GlobeNewsWire

Harvard Bioscience Announces the Successful Completion of Debt Refinancing with Comprehensive Growth Financing Package

Completes Repayment of Existing Credit Agreement, Extends Debt Maturity, and Enhances Financial Flexibility BroadOak Partner Bill Snider to Join Board of Directors and Company to Form Advisory Board o...

3 months ago - GlobeNewsWire

Harvard Bioscience Announces Third Quarter 2025 Financial Results

Reports Q3 2025 Revenues of $20.6M, Gross Margin of 58.4%, and Positive Cash Provided by Operations Company Expects to Refinance or Repay the Debt in the Fourth Quarter Fourth Quarter 2025 Guidance Re...

5 months ago - GlobeNewsWire

Harvard Bioscience Schedules Third Quarter 2025 Earnings Conference Call for November 6, 2025 at 8:00 AM ET

HOLLISTON, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2025, before the market opens on Nov...

5 months ago - GlobeNewsWire

Harvard Bioscience Expands Distribution Agreement with Fisher Scientific to Include United States

HOLLISTON, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), a leading provider of innovative laboratory equipment, is pleased ...

6 months ago - GlobeNewsWire

Harvard Bioscience Announces Appointment of Stephen DeNelsky to Board of Directors

HOLLISTON, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced the appointment of Stephen DeNelsky to its Board of...

7 months ago - GlobeNewsWire

Harvard Bioscience Announces Second Quarter 2025 Financial Results

Reports Q2 2025 Revenues of $20.5M, Gross Margin of 56.4%, and Positive Cash Provided by Operations Third Quarter 2025 Guidance Reflects Improved Operations and Strong Financial Discipline New Credit ...

8 months ago - GlobeNewsWire

Harvard Bioscience Schedules Second Quarter 2025 Earnings Conference Call for August 11, 2025 at 8:00 AM ET

HOLLISTON, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended June 30, 2025, before the market opens on August 1...

8 months ago - GlobeNewsWire

Harvard Bioscience Announces CEO Succession Plan & Appointment of Two New Independent Directors to Board

HOLLISTON, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced a CEO succession plan under which John Duke will ass...

9 months ago - GlobeNewsWire

Harvard Bioscience Appoints John Duke to Board of Directors

HOLLISTON, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the appointment of John Duke to its board of directors, effective June 2, 20...

10 months ago - GlobeNewsWire

Harvard Bioscience Announces First Quarter 2025 Financial Results

HOLLISTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2025.

11 months ago - GlobeNewsWire

Harvard Bioscience Schedules First Quarter 2025 Earnings Conference Call for May 12, 2025 at 8:00 AM ET

HOLLISTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2025, before the market opens on May 12, ...

11 months ago - GlobeNewsWire

Harvard Bioscience Announces CFO Transition

HOLLISTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the resignation of Jennifer Cote, the Company's Chief Financial Officer and...

1 year ago - GlobeNewsWire

Harvard Bioscience, Inc. to Participate in Two Investor Conferences in March 2025

HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Of...

1 year ago - GlobeNewsWire

Harvard Bioscience Announces Fourth Quarter and Full-Year 2024 Financial Results

HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and full year ended December 31, 2...

1 year ago - GlobeNewsWire

Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology Meeting

Advanced platforms for CROs, pharmaceutical and biotech companies seeking to enhance productivity Advanced platforms for CROs, pharmaceutical and biotech companies seeking to enhance productivity

1 year ago - GlobeNewsWire

Harvard Bioscience Schedules Fourth Quarter 2024 Earnings Conference Call for March 12, 2025 at 8:00 AM ET

HOLLISTON, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2024, before the market opens on Marc...

1 year ago - GlobeNewsWire

Harvard Bioscience, Inc. to Participate in the Sidoti Micro Cap Conference

HOLLISTON, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Off...

1 year ago - GlobeNewsWire

Harvard Bioscience Schedules Third Quarter 2024 Earnings Conference Call for November 7, 2024 at 8:00 AM ET

HOLLISTON, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2024 before the market opens on Nove...

1 year ago - GlobeNewsWire

Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Safety Pharmacology Society Annual Meeting

Solutions for CROs, pharma and biotechs streamline testing and enable fundamental advancements in preclinical and organoid focused therapy development Solutions for CROs, pharma and biotechs streamlin...

1 year ago - GlobeNewsWire